Endoscopic Gastric Reduction of Gastric Mucosa in Obesity

Launched by ZAGAZIG UNIVERSITY · Jan 19, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new procedure called endoscopic gastric reduction, which aims to help people with obesity. It focuses on certain cells in the stomach that produce a hormone called ghrelin, which increases appetite and food intake. By reducing these cells, the researchers hope to help patients manage their weight and improve related health issues, such as diabetes and fatty liver disease.

To participate in this trial, individuals must be between the ages of 65 and 74 or 18 and 62, have a body mass index (BMI) over 25, and have a diagnosis of diabetes, cardio-metabolic syndrome, or fatty liver disease. However, those with certain conditions like active peptic ulcers, serious mental health issues, or specific blood disorders won't be eligible. Participants can expect to undergo the endoscopic procedure, and throughout the trial, they will be closely monitored for their health and progress. This study is currently recruiting, so it’s an opportunity for eligible individuals to potentially benefit from this innovative treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • body mass index more than 25
• • diagnosis of diabetes mellitus.
• • diagnosis of cardio-metabolic syndrome.
• • fatty liver disease diagnosed by abdominal ultrasound.
• Exclusion Criteria:
• • use of drugs which induce insulin resistance, diabetes and hepatic steatosis.
• • excess alcohol consumption.
• • chronic gastritis, active peptic ulcer.
• • malignancy.
• • depression and severe psychological disorders
• • inability to give informed consent.
• • coagulopathy (INR more than 1.5, platelets less than 50000 per cmm).
• • severe cardiopulmonary comorbidity.